Slow-Reflow and Prognosis in Patients with High Parathyroid Hormone Levels Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction-Reference-Cited by-同舟云学术

Slow-Reflow and Prognosis in Patients with High Parathyroid Hormone Levels Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

Published:2023-11-14 Issue: Volume: Page:
ISSN:1937-5387
Container-title:Journal of Cardiovascular Translational Research
language:en
Short-container-title:J. of Cardiovasc. Trans. Res.

Author:

Wu Gangyong^ORCID,Wu Zufei,Xu Baida,Chen Shi,Su Wentao,Liu Yehong,Wu Ting,Shen Qin,Zong Gangjun

Funder

the Innovation and Application Project of Medical and Public Health Technology of Wuxi Science and Technology Bureau

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Cardiology and Cardiovascular Medicine,Pharmaceutical Science,Genetics,Molecular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12265-023-10457-8.pdf

Reference32 articles.

1. Gao G, Xu H, Zhang D, Song C, Guan C, Xu B, et al. The predictive value of baseline target lesion SYNTAX score for no-reflow during urgent percutaneous coronary intervention in acute myocardial infarction. J Interv Cardiol. 2021;2021:9987265. https://doi.org/10.1155/2021/9987265.

2. Tasar O, Karabay AK, Oduncu V, Kirma C. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2019;30(4):270–6. https://doi.org/10.1097/MCA.0000000000000726.

3. Niu X, Zhang J, Bai M, Peng Y, Sun S, Zhang Z. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC Cardiovasc Disord. 2018;18(1):3. https://doi.org/10.1186/s12872-017-0722-z.

4. Isaksson E, Almquist M, Seeberger A, Sterner G. Is low pre-transplant parathyroid hormone a risk marker for cardiovascular disease in long-term follow-up of renal transplant recipients? Clin Exp Nephrol. 2018;22(5):1188–97. https://doi.org/10.1007/s10157-018-1543-9.

5. Radhakrishnan A, Pickup LC, Price AM, Law JP, Edwards NC, Steeds RP, et al. Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy? Heart. 2019;105(17):1302–9. https://doi.org/10.1136/heartjnl-2019-315138.